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Abstract
Interruption of the enterohepatic circulation of bile acids increases cholesterol catabolism, thereby stimulating hepatic
cholesterol synthesis from acetate. We hypothesized that such treatment should lower the hepatic acetate pool which may
alter triglyceride and glucose metabolism. We explored this using mice deficient of the ileal sodium-dependent BA
transporter (Slc10a2) and ob/ob mice treated with a specific inhibitor of Slc10a2. Plasma TG levels were reduced in Slc10a2-
deficient mice, and when challenged with a sucrose-rich diet, they displayed a reduced response in hepatic TG production
as observed from the mRNA levels of several key enzymes in fatty acid synthesis. This effect was paralleled by a diminished
induction of mature sterol regulatory element-binding protein 1c (Srebp1c). Unexpectedly, the SR-diet induced intestinal
fibroblast growth factor (FGF) 15 mRNA and normalized bile acid synthesis in Slc10a22/2 mice. Pharmacologic inhibition of
Slc10a2 in diabetic ob/ob mice reduced serum glucose, insulin and TGs, as well as hepatic mRNA levels of Srebp1c and its
target genes. These responses are contrary to those reported following treatment of mice with a bile acid binding resin.
Moreover, when key metabolic signal transduction pathways in the liver were investigated, those of Mek1/2 - Erk1/2 and Akt
were blunted after treatment of ob/ob mice with the Slc10a2 inhibitor. It is concluded that abrogation of Slc10a2 reduces
hepatic Srebp1c activity and serum TGs, and in the diabetic ob/ob model it also reduces glucose and insulin levels. Hence,
targeting of Slc10a2 may be a promising strategy to treat hypertriglyceridemia and diabetes.
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Introduction
Bile acids (BAs) are crucial for the intestinal absorption of
dietary fatty acids, cholesterol and fat-soluble vitamins. Distur-
bances in BA metabolism can initiate malabsorption and
cholelithiasis but may also be important in the development of
hyperlipidemia and arteriosclerosis [1]. Over 95% of the intestinal
BAs are absorbed and returned to the liver. Since the entire pool
of BAs circulates 4–10 times per day, a reduced intestinal
absorption of BAs by merely a few percent will significantly
increase the daily fecal excretion of BAs. The intestinal absorption
of BAs is largely an active process where the BA transporter
Slc10a2, also known as ileal sodium/BA cotransporter (Ibat) or
apical sodium-dependent BA transporter (Asbt), is of major
importance [2]. The BAs regulate their own synthesis, thereby
securing a constant pool of BAs [1]. This is largely exerted at the
level of the rate-limiting microsomal enzyme cholesterol 7a-
hydroxylase (Cyp7a1) by feedback inhibition [1]. In addition to
this direct feed-back by the BAs in the liver, mediated by the
farnesoid X receptor (Fxr), regulation of Cyp7a1 gene expression
is also exerted by cholesterol through an liver X receptor (Lxr)-
mediated feed-forward mechanism in rodents [3] and by various
hormones, although the mechanisms for the latter are still unclear.
Finally, hepatic BA synthesis may also be controlled by fibroblast
growth factor (FGF)15 (FGF19 in humans) secreted from the
intestine. The production of this proposed enterokine is stimulated
by activation of Fxr presumably when BAs traverse the enterocyte.
Circulating FGF15 is thought to bind to its receptor FGFr4 in the
liver leading to suppression of Cyp7a1 [1].
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achieved by the removal of the distal ileum [4,5], or by the
administration of BA-binding resins [6]. These treatments elicit a
compensatory increase in BA synthesis which enhances the
hepatic demand for cholesterol. This is met by an induced
hepatic synthesis of cholesterol and an increased hepatic uptake
of circulating cholesterol-rich lipoproteins; the latter leading to
reduced plasma cholesterol levels [6,7]. The effects of Slc10a2
deficiency on BA metabolism in mice have previously been
described [2]. In male Slc10a22/2 mice, the fecal BA excretion
is increased by 8 to 24-fold, and the total pool of BAs is reduced
by ,80%. No other major active uptake mechanism for
intestinal BAs was identified. The activity of the rate-limiting
enzyme in BA synthesis, Cyp7a1, was increased 2.5-fold and its
mRNA levels and protein mass were increased 4-fold. The loss of
BAs in Slc10a22/2 animals creates an increased hepatic
demand for cholesterol that in turn consumes precursors for
cholesterol synthesis. Since cholesterol and triglyceride (TG)
synthesis share the mutual precursor acetyl-CoA, an important
question is therefore whether chronic BA loss might alter hepatic
TG and glucose homeostasis. In humans, treatment with BA-
binding resins often increases plasma TGs due to enhanced
VLDL synthesis [8,9,10], and BA malabsorption has been
postulated as an underlying defect in familial hypertriglyceride-
mia [11].
In the present study, the aim was to evaluate if interruption of
BA circulation by genetic deletion or pharmacological inhibition
of Slc10a2 alters TG and glucose metabolism. Surprisingly, mice
deficient in Slc10a2 had reduced plasma TG levels. Further, the
increase in hepatic TG content following feeding a sucrose-
enriched diet was attenuated in Slc10a22/2 mice. In line with this
finding, expression of sterol regulatory element-binding protein 1c
(Srebp1c) and its target genes were reduced in Slc10a22/2 mice.
Specific pharmacological inhibition of the Slc10a2 protein in
hyperlipidemic ob/ob mice reduced blood glucose, insulin and
serum TGs. Also, hepatic Srebp1c lipogenic target genes and
gluconeogenic genes were reduced, together with an altered signal
transduction pattern. The data show that interruption of BA
recirculation through abrogation of Slc10a2 reduces plasma TG
levels accompanied by reduced hepatic Srebp1c, a response
previously not recognized.
Materials and Methods
Ethics Statement
All animal care and experiments were conducted in accordance
with accepted national standards of humane animal care and
approved by the Ethics Committee of the University of
Gothenburg (Permit Numbers: 140–2005 and 84–2002).
Animals and Diets
Slc10a2+/2 and Slc10a22/2 mice were generated at Astra-
Zeneca R&D, Mo ¨lndal, as detailed in supplemental experimental
procedures (Text S1) based on the outline of Dawson et al [2].
Throughout the study male mice were used. In the experiments
shown in Figure 1 and 2 mice were 20 weeks and in Figure 3, 33
weeks old. A sucrose-rich diet (61% sucrose, D12329, Research
Diets, NJ), together with drinking water supplemented with 10%
fructose, was used for the high-carbohydrate experiment. Animals
had free access to the diet for two weeks. If not stated otherwise, all
other animals received standard mouse chow (R3; Lactamin AB,
Stockholm, Sweden) containing (energy %) 12% fat, 62%
carbohydrates, and 26% protein, with a total energy content of
12.6 kJ/g and tap water. There were no additions of cholesterol to
the diets. Male ob/ob animals 10–12 weeks old were from Taconic
A/S, DK. Ob/ob animals were gavaged with a specific Slc10a2
inhibitor AZD 7806 (AstraZeneca R&D, Mo ¨lndal, Sweden) that is
not absorbed and therefore lacks systemic side effects, (AZD7806 is
not equivalent to PR835 in ref. [12]) or a control vehicle for 11
days. Animals had free access to food and water. Since it is known
that at least BA and cholesterol synthesis pathways are subject to
diurnal variation, including higher order circadian regulation,
blood and tissue sampling were standardized and performed in the
morning to minimize circadian effects. All animal care and
experiments were conducted in accordance with accepted
standards of humane animal care and approved by the Ethics
Committee of the University of Gothenburg (Permit Numbers:
140–2005 and 84–2002).
Plasma Analysis
Blood was centrifuged, and plasma was analyzed for total
cholesterol and TGs using the IL Tests cholesterol 181618–10 and
TG 181610–60 kits on the Monarch 2000 system (IL Scandinavia,
Gothenburg, Sweden). Lipoprotein cholesterol profiles were
obtained by separation of 10 ml of plasma using a micro fast
protein liquid chromatography (FPLC) system [13]. Plasma insulin
levels were analyzed using a rodent insulin RIA kit (Linco, St.
Charles, MI). Total plasma glucose was analyzed using the IL Test
(IL Scandinavia, Gothenburg, Sweden) on the Monark 2000
system. Blood glucose was determined using a Bayer Elite
glucometer (Bayer diagnostics, Germany). Plasma free fatty acids
were analyzed employing a commercial NEFA kit (Wako
Chemicals USA Inc. Richmond, Virginia). Serum levels of 7a-
hydroxy-4-cholesten-3-one (C4) were used as an indirect mea-
surement of Cyp7a1 activity, and analyzed in either pooled or
individual plasma samples by high pressure liquid chromatogra-
phy [14].
Enzymatic Activities
Enzyme activities of 3-hydroxy-3-methylglutaryl-CoA (HMG-
CoA) reductase and of cholesterol 7alpha hydroxylase (Cyp7a1)
were assayed in hepatic microsomes, as described [15]. In this
assay there was no addition of cholesterol - the endogenous
cholesterol is utilized as substrate.
RNA Extraction and Quantitative Real Time PCR
Total RNA was extracted from frozen livers or distal ileum with
TRIzol reagent (Invitrogen, Carlsbad, CA). The RNA was DNase-
treated with RQ1 Dnase (Promega, Madison, WI). cDNA
synthesis and quantitative real time PCR was performed
employing HPRT as endogenous control [16]. Primer and probe
information are available on request.
Immunoblotting of Liver Proteins
A ligand blot using
125I-labeled rabbit b-VLDL as probe was
used to detect LDL receptors in liver as described [17].
Hepatic scavenger receptor class B type 1 (Srb1) was assayed by
immunoblot using a rodent specific rabbit polyclonal antibody
(Novus Biologicals Inc., Littleton, CO) as described [18]. Cyp7a1
protein levels were assayed in liver microsomal protein samples by
immunoblot using a rabbit polyclonal antibody directed against
the C’-terminus of the Cyp7a1 [16].
To detect Srebp1 protein, cytoplasmic and nuclear protein
preparations from liver were performed using the NE-PER
reagent (Pierce), including Complete protease inhibitor (Roche),
1 mM phenyl-methylsulfonyl fluoride, 0.5 mM leupeptin, 5 mg/
ml Calpain inhibitor I (Biomol, PA), following the manufacturer’s
Bile Acid Circulation and Lipogenesis
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37787Figure 1. Disruption of the ileal BA transporter gene Slc10a2 activates enzymes in BA synthesis. (A) mRNA levels of cholesterol 7a-
hydroxylase (Cyp7a1) in livers of wt, Slc10a2+/2 and Slc10a22/2 animals. (B) Cyp7a1 enzymatic activity in pooled microsomal samples from livers of
wt, Slc10a2+/2 and Slc10a22/2 animals. Results shown are mean of two analyses. (C) Protein levels of Cyp7a1 in livers of wt, Slc10a2+/2 and
Slc10a22/2 mice determined in pooled microsomal samples by immunoblot using a Cyp7a1-specific antibody. 20 mg and 40 mg of protein were
used per sample, respectively. The results are representative of three separate immunoblots. Note the loading order of the samples. (D) Serum levels
of the Cyp7a1 activity marker 7a-hydroxy-4-cholesten-3-one (C4) were assayed as an indirect measure of Cyp7a1 enzymatic activity in pooled serum
samples of wt, Slc10a2+/2 and Slc10a22/2 animals. Data show mean of two separate measurements. (E) hepatic mRNA levels of 12a-hydroxylase
(Cyp8b1), and (F) hepatic small heterodimer partner (Shp) mRNA levels of wt, Slc10a2+/2 and Slc10a22/2 mice. mRNA levels for the wt mice were
normalized to 1. Data are expressed as mean 6 standard error (SEM) for the mRNA analysis. wt littermates (n=10), Slc10a2+/2 (n=9) and Slc10a22/
2 (n=10) for A-F. Significances of differences between groups was tested by Dunnetts test; a p-value ,, 0.01 is denoted **.
doi:10.1371/journal.pone.0037787.g001
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37787Figure 2. Ablation of the Slc10a2 gene lowers the levels of plasma s TGs but not cholesterol. (A) Total plasma cholesterol and TGs from
wt, Slc10a2+/2 and Slc10a22/2 mice. (B) Plasma profiles of cholesterol and TGs (C) were analysed from wt, Slc10a2+/2 and Slc10a22/2 animals by
fast protein liquid chromatography (FPLC). Lines represent means of all individuals from each group, respectively. Lipoprotein fractions are indicated,
n=9–10. (D) Hepatic 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase mRNA levels and enzymatic activity of wt, Slc10a2+/2 and Slc10a22/2
mice. HMG-CoA reductase enzymatic activity was analyzed from pooled hepatic microsomal samples and represents mean of two measurements.
(n=9–10). (E) Hepatic mRNA levels of the sterol transporters ATP-binding cassette sub-family G member 5 (Abcg5) and Abcg8 in wt, Slc10a2+/2 and
Slc10a22/2 mice. (F) Hepatic mRNA levels of sterol regulatory element-binding protein 1c (Srebp1c) and Srebp2, in wt, Slc10a2+/2 and Slc10a22/2
mice. mRNA levels in wt mice were normalized to 1. Data are expressed as mean 6 standard error (SEM) for the mRNA and total plasma cholesterol
and TGs analyzes. wt littermates (n=10), Slc10a2+/2 (n=9) and Slc10a22/2 (n=10) for A-F. Significances of differences between groups was tested
by Dunnetts test, a p-value ,0.05 is denoted *.
doi:10.1371/journal.pone.0037787.g002
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37787Figure 3. Slc10a22/2 mice display lower hepatic TGs and cholesterol than wild type mice. (A) Liver TGs and cholesterol content were
analyzed from a total of four groups; wt and Slc10a22/2 mice fed either standard mouse chow or a sucrose-rich (SR) diet (Materials and Methods) for
two weeks. (B) Hepatic mRNA levels of ATP-citrate lyase (Acl), acetyl-CoA carboxylase (Acc), fatty acid synthase (Fas) and stearoyl-CoA desaturase 1
(Scd1), enzymes involved in fatty acid synthesis from wt or Slc10a22/2 animals, as in (A). (C) Sterol regulatory element-binding protein 1 (Srebp1)
Bile Acid Circulation and Lipogenesis
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50 mg and 25 mg respectively, were electrophoresed on NuPage
Bis-Tris gels (Invitrogen) and transferred to nitrocellulose mem-
branes. Membranes were blocked in 5% skim milk powder and
incubated with a mouse monoclonal antibody raised against the
N’-terminus of Srebp1 (Labvision Corporation, CA) at 1.5 mg/mL
in 5% skim milk powder for two hours at room temperature. An
HRP conjugated goat anti-mouse F(ab’)2 antibody (Pierce) was
used for detection of specific signals together with Supersignal
reagent (Pierce) and a Fuji BAS 1800 analyzer (Fuji Photo Film
Co.). Lamin AB was obtained from Cell signaling TechnologyH,
Boston, Mass.
To analyze phosphorylated liver proteins by Western blot, total
liver protein homogenates were prepared from frozen tissue by
homogenization using a polytron followed by sonication in a buffer
containing 20 mM Tris-Hcl, pH 7,4, 1% Triton X-100, 10%
glycerol, 150 mM NaCl, 2 mM EDTA, 25 mM beta-glycero-
phosphate, 20 mM sodium floride, 1 mM sodium orthovanadate,
2 mM sodium pyrophosphate, 1 mM benzamidine, 1 mM phe-
nyl-methylsulfonyl fluoride, 0.5 mM leupeptin, Complete protease
inhibitor (Roche), and then centrifuged at 14 000 rpm in a
microcentrifuge, and the supernatant was recovered. 50 mgo f
protein was loaded on NuPage Bis-Tris gels (Invitrogen) and
transferred to nitrocellulose membranes. Membranes were
blocked in Starting Block-PBS (Pierce) and incubated in 3%
BSA with phosphorylation site specific antibodies, pAkt1, pErk1/2
and pMek1/2, as indicated in figures, overnight at +4uC, then
stripped with Restore (Pierce), reprobed with antibodies detecting
total amounts of Akt1, Mek1/2 and Erk1/2, and finally stripped
and reprobed with an antibody against beta-actin (Abcam) to
verify equal gel loading. Antibodies against kinases were purchased
from Cell Signaling Technology, Inc. Blots were developed as
described above.
Determination of liver TGs and cholesterol
Liver cholesterol and TG were extracted as previously described
[19] and determined using commercially available kits (Roche
Applied Science, Indianapolis).
Statistics
Data are shown as mean +/2 SEM and were log transformed
prior to statistical analysis. The significance of differences between
groups was tested as indicated in Figure legends, by 1-way
ANOVA followed by post-hoc comparisons according to Dunnett
or by Student’s t-test using GraphPad PrismH Software.
Results
Generation of Slc10a22/2 Mice
Generation of Slc10a22/2 mice was performed as described in
detail in supplemental experimental procedures (Text S1).
Southern blotting, quantitative real time PCR and immunoblot-
ting confirmed appropriate targeting and lack of Slc10a2
expression in the null mice (Figure S1 and not shown.)
Slc10a22/2 animals were viable and fertile. No abnormalities
in behaviour, gross appearance, body weight or survival were seen,
consistent with the previous report by Dawson et al. [2].
Increased BA synthesis in Slc10a2+/2 and Slc10a22/2
Mice
An established response following disruption of the enterohe-
patic circulation of BAs is an induced synthesis of BAs
[2,4,5,6,20]. Indeed, when the hepatic mRNA levels for Cyp7a1,
the rate-limiting enzyme in BA synthesis, were assayed by
quantitative real time PCR (qrtPCR), there was an ,7-fold
induction in Slc10a22/2 mice (Figure 1A). Also, in the
Slc10a2+/2 mice there was a clear but less pronounced (,3-
fold) increase in Cyp7a1 mRNA.
Consistent with the Cyp7a1 mRNA increase, the enzymatic
activity and the protein mass of Cyp7a1 were higher in both
Slc10a2+/2 and 2/2 mice, when examined in pooled micro-
somes (Figures 1B and 1C). The Cyp7a1 reaction product 7a-
hydroxy-4-cholesten-3-one (C4), present in blood serum, has been
demonstrated to be an accurate marker of Cyp7a1 enzyme activity
[14]. Analysis of pooled serum from both heterozygous and
homozygous animals revealed higher serum C4 levels as compared
to control animals (Figure 1D).
In conjunction with the observed increase in Cyp7a1, the
mRNA levels for the sterol 12a-hydroxylase (Cyp8b1) were also
induced dose-dependently (Figure 1E). When the circulation of
BAs is disrupted, the amount of available ligand for the hepatic
nuclear BA receptor Fxr decreases. In line with this, decreased
hepatic mRNA levels of the Fxr target gene small heterodimer
partner (Shp), a suppressor of Cyp7a1 gene transcription, were
found in heterozygous and homozygous mice, with the most
pronounced change in the latter group (Figure 1F).
Lowered Plasma TGs in Slc10a2+/2 and Slc10a22/2
Mice
Plasma total TGs were significantly reduced by 22% in
Slc10a2+/2 mice and by 35% in Slc10a22/2 mice compared
to controls (Figure 2A). The plasma cholesterol and TG
lipoprotein profiles were then analyzed by FPLC (Figure 2B and
C). The plasma cholesterol profiles did not vary notably between
controls and homozygous animals. However, larger changes were
found in the plasma TG profiles of these mice (Figure 2C). In
Slc10a2+/2 mice, TGs were reduced within LDL, whereas in
Slc10a22/2 mice TGs were reduced in both VLDL- and LDL
(Figure 2C). Plasma glucose and insulin were not altered in
Slc10a22/2 animals (not shown).
Adaptation of Hepatic Cholesterol Metabolism to BA
Deficiency
There were no changes in the hepatic expression of the LDL-
receptor or the HDL-receptor (Srb1), neither at mRNA nor at
protein levels (not shown). The high demand for cholesterol as
substrate for Cyp7a1 in the livers of Slc10a2+/2 and Slc10a22/2
mice was reflected in increased enzymatic activity of the hepatic
HMG-CoA reductase, with a 2-fold increase in the heterozygous
and a 3.5-fold increase in homozygous animals, based upon
immunoblots were performed on pooled liver cytoplasmic and nuclear protein preparations, respectively, from wt or Slc10a22/2 mice fed a regular
chow or a SR diet using an antibody specific for the N’-terminus of Srebp1. An antibody against lamin was used as nuclear loading control. The blot is
representative of three separate immunoblots. Hepatic mRNA expression levels of (D), glucokinase (Gk); pyruvate kinase (Lpk); (E) glucose-6-
phosphate dehydrogenase (G6pdh); malic enzyme (Me). mRNA values in the wt group fed regular chow were normalized to 1. (F) Fibroblast growth
factor 21, FGF(21). mRNA values in the wt group on regular chow were normalized to 1. Data are expressed as mean 6 standard error (SEM) for the
mRNA, hepatic cholesterol and TG analysis. wt (n=6), Slc10a22/2 (n=5), wt + SR (n=6) and Slc10a2+/2 +SR (n=6) for A-D. Significances of
differences between groups were tested by Student’s t test, a p-value ,0.05 is denoted *. p,0.01 is denoted **.
doi:10.1371/journal.pone.0037787.g003
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in hepatic HMG-CoA reductase mRNA levels had a similar
pattern, although smaller differences were observed between
groups (Figure 2D). The gene expression of the hepatic sterol
transporters ATP-binding cassette sub-family G member 5 (Abcg5)
and Abcg8 were suppressed by up to 50% in a gene-dose
dependent manner (Figure 2E).
In line with the findings for HMG-CoA reductase, the hepatic
levels of Srebp2 mRNA were increased in both Slc10a2+/2 and
Slc10a22/2 mice (Figure 2F). Intriguingly, the regulation of the
Srebp1c gene in the liver displayed an opposite pattern, with
reduced mRNA levels in heterozygous and homozygous mice
compared to controls, again in a gene-dose dependent manner
(Figure 2F).
Hepatic TG Production is Suppressed in Slc10a22/2
Mice
To further explore TG metabolism in this animal model of BA
malabsorption, Slc10a22/2 and wt control animals received a
sucrose-rich diet (SR diet) for two weeks to increase substrate
availability, while animals on chow served as controls. For both
diets, neither plasma glucose, insulin nor food intake were
significantly different between Slc10a22/2 and respective wt
control group, (not shown).
The hepatic TG content tended to be lower in Slc10a22/2
mice fed regular chow (Figure 3A). This difference was more
evident on the SR diet where hepatic TGs increased by 120% in
wt animals, whereas in Slc10a22/2 animals this increase was
significantly blunted (Figure 3A). Also, hepatic cholesterol was
lower in Slc10a22/2 mice fed the SR diet compared to wt
controls on this diet (Figure 3A). Since the lower hepatic TG levels
in Slc10a22/2 mice on the SR-diet could be due to decreased
fatty acid synthesis we measured the mRNA levels of ATP-citrate
lysase (Acl), acetyl-CoA carboxylase (Acc), fatty acid synthase (Fas)
and stearoyl-CoA desaturase 1 (Scd1), by qRT PCR. The gene
expression of these enzymes appeared reduced in the livers of
Slc10a22/2 animals (Figure 3B); this finding was more pro-
nounced when animals were challenged with the SR diet. The
transcription factor Srebp1c is crucial for optimal activation of
most genes in fatty acid synthesis [21]. The expression of the
Srebp1c protein (mature and precursor form) was reduced in
Slc10a22/2 mice, as evaluated by Western blot on cytoplasmic
and nuclear proteins using an antibody against the N’-terminus of
Srebp1c (Figure 3C).
Disruption of BA circulation by Slc10a2 gene deletion alters the
expression of genes involved in hepatic glucose handling.
Hepatic TG synthesis is dependent on substrates in the
glycolytic pathway and thus on the activity and gene expression
of glucose metabolizing enzymes [22]. The mRNA levels of the
hepatic glycolytic enzyme glucokinase (Gk) were unaltered in
Slc10a22/2 animals as compared to wt controls, both on chow
and on the SR diet (Figure 3D). However, the mRNA levels of
liver pyruvate kinase (Lpk) were reduced 30% in Slc10a22/2 on
chow (Figure 3D). mice Interestingly, feeding the SR diet resulted
in a much stronger up-regulation of Lpk mRNA in Slc10a22/2
mice (4.3-fold), whereas in wt control animals there was a more
modest 1.8-fold stimulation under the same conditions. Determi-
nation of the NADPH generating enzyme glucose-6-phosphate
dehydrogenase (G6pdh) mRNA showed increased levels in
Slc10a22/2 animals as compared to wt mice on regular chow
(Figure 3E). Feeding the SR diet resulted in a three-fold increase of
G6pdh mRNA in wt mice, whereas in Slc10a22/2 mice there
was only a modest 60% increase (Figure 3E). It was therefore of
interest to determine if the gene expression of malic enzyme (Me),
also part of a NADPH-generating step converting malate to
pyruvate, was changed in Slc10a22/2 livers. As seen from
Figure 3E, Me mRNA tended to decrease in Slc10a22/2 mice on
regular chow and increased during the SR diet to similar extents in
wt and Slc10a22/2 animals.
Normalization of Increased BA Synthesis in Slc10a22/2
Mice Following a SR Diet
We next examined whether the SR diet had any effect on BA
synthesis. Surprisingly, the elevated Cyp7a1 expression in
Slc10a22/2 mice was dramatically suppressed to levels seen in
wt animals when Slc10a22/2 mice were fed the SR diet
(Figure 4A), and there was no difference in BA synthesis between
Slc10a22/2 and wt on the SR diet. Also, the wt controls receiving
the SR diet displayed a lower gene expression of Cyp7a1.
Estimation of the level of BA synthesis by measurement of the
serum marker C4 confirmed that the high enzymatic activity of
Cyp7a1 was reduced following the SR diet to the Slc10a22/2
animals. However, the serum C4 levels were not reduced in wt
animals on the SR diet (Figure 4B).
Since the stimulated Cyp7a1 expression in Slc10a22/2
appeared concomitantly with reduced SHP levels (Figure 1) we
evaluated whether the suppressed Cyp7a1 expression may be
linked to increased SHP levels. Assay of SHP mRNA (Figure 4C)
showed that the reduced levels of SHP in the Slc10a22/2 mice
were indeed normalized following the SR diet, although the
reduction of SHP seen in the Slc10a22/2 mice in this experiment
did not reach statistical significance.
We also examined the mRNA levels of key enzymes in sterol
synthesis, HMGCoA synthase and HMGCoA reductase, during
SR feeding since the increased demand for cholesterol in
Slc10a22/2 mice was obviously met by increased de novo
synthesis. The HMGCoA synthase and HMGCoA reductase
mRNA levels were increased in Slc10a22/2 animals on normal
diet whereas the levels were reduced in both wt and Slc10a22/2
mice when fed the SR diet (Figure 4D). These findings were in line
with concomitantly altered mRNA levels for SREBP2 (Figure 4D).
There was no difference in total liver cholesterol in Slc10a22/2
mice on chow as compared to wt mice (Figure 3A). However, the
SR diet clearly increased total liver cholesterol in both types of
mice - notably to a higher extent in the wt mice (Figure 3A).
Inhibition of Slc10a2 in ob/ob Mice Reduces Plasma
Glucose and TGs
Although serum glucose in Slc10a22/2 mice was not changed,
these animals were hypolipidemic. We therefore evaluated if
beneficial effects could be obtained in ob/ob mice, a model where
plasma glucose and TGs are chronically elevated. Ob/ob mice
were treated with the specific Slc2a10 inhibitor AZD7806 for 11
days. Fasting glucose levels were reduced 30% in drug-treated ob/
ob mice compared to vehicle-treated animals (Figure 5A).
Likewise, this treatment reduced fasting insulin levels by 50%
and total plasma TG levels by 73%, whereas total plasma
cholesterol tended to increase slightly (+16%) (Figure 5B).
As expected, the hepatic mRNA level of Cyp7a1 increased in
drug-treated mice (Figure 5C), further, the level of HMG-CoA
reductase increased 2-fold (not shown). When the hepatic contents
for cholesterol and TGs were analyzed, there were no differences
between inhibitor-treated and control animals (Figure 5D). To get
indications of that Slc10a2 activity was blocked, the mRNA levels
of the Fxr target genes FGF15, Shp and ileal BA binding protein
(Ibabp) were assayed in samples from the distal ileum; they were all
significantly reduced in response to treatment as could be expected
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37787Figure 4. A sucrose-rich (SR) diet normalizes elevated CYP7A1 levels and induces the expression of the metabolic regulators FGF15
and FGF21 in Slc10a22/2 mice. Livers from wt and Slc10a22/2 mice fed regular chow or a SR diet were analysed for A), mRNA levels of Cyp7a1;
B), Serum C4 levels, a marker of Cyp7a1 enzymatic activity; C), hepatic mRNA levels of SHP; and for D), HMGCoA synthase, HMGCoA reductase and
SREBP2 mRNA. In panel E, FGF15, SHP and IBABP mRNA levels were determined in samples from distal ileum of wt and Slc10a22/2 mice fed regular
diet or the SR diet. Data are expressed as mean 6 standard error (SEM), n=5–6. mRNA expression for the wt group on regular chow is normalized to
1. Significances of differences between groups were tested by Student’s t test, a p-value ,0.05 is denoted *. p,0.01 is denoted **.
doi:10.1371/journal.pone.0037787.g004
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37787Figure 5. Inhibition of the Slc10a2 protein improves plasma glucose and TGs in ob/ob mice. Ob/ob mice were treated with a specific
Slc10a2 protein inhibitor, (AZD7806), or control vehicle (vehicle) (see experimental procedures). (A) fasting levels of blood glucose and plasma insulin.
(B) plasma total TGs and cholesterol. (C) Hepatic mRNA levels of fibroblast growth factor 21 (FGF21) and cholesterol 7a-hydroxylase (Cyp7a1). (D)
Liver cholesterol and TGs. (E) Distal ileum mRNA levels of FGF15, small heterodimer partner (Shp), Ileal BA binding protein (Ibabp) and farnesoid X
receptor (Fxr) from ob/ob animals treated with a Slc10a2 protein inhibitor. mRNA levels of the control vehicle treated animals are normalized to 1.
Data are represented as mean 6 standard error (SEM). Significances of differences between groups was tested by Student’s t test, a p-value ,0.05 is
denoted *. P,0.01 is denoted **.
doi:10.1371/journal.pone.0037787.g005
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The gene expression of Fxr was unaltered in the distal ileum
following treatment with the Slc10a2 inhibitor (Figure 5E).
Inhibition of Ileal Slc10a2 in ob/ob Mice Reduces Srebp1c
and its Target Genes in the Liver
Since dysregulation of Srebp1c has been reported to be a major
determinant of the increased lipogenic response in ob/ob liver,
ultimately leading to reduced hepatic insulin sensitivity, we next
analyzed the gene expression of hepatic Srebp1c and three of its
target genes. In accordance with the reduced Srebp1c levels
observed in Slc10a22/2 mice both under basal and SR diet
challenge, markedly reduced mRNA levels of Srebp1c were
observed in response to administration of the Slc10a2 inhibitor to
ob/ob mice (Figure 6A). Moreover, the mRNA levels of the
Srebp1c liver target genes Acc and Fas were strongly decreased, by
50% and 80%, respectively (Figure 6A). However, the Scd1
mRNA level was not significantly altered compared to vehicle-
treated controls (Figure 6A).
Altered Expression of Hepatic Glucose Metabolic Genes
in Slc10a2-inhibitor Treated ob/ob Mice
Next we investigated the expression levels of enzymes
important for glucose handling in the livers of ob/ob mice
treated with Slc10a2 inhibitor. As seen in Figure 6B, the mRNA
level for Gk, the initial step in glycolysis, was increased in treated
mice, in line with decreased blood glucose levels. However, in
contrast, mRNA for the glycolytic gene Lpk was reduced by 30%
(Figure 6B). A similar result for the Lpk mRNA was also found
in the Slc10a22/2 livers (Figure 3D). We also analyzed the
expression of the gluconeogenic genes glucose 6-phosphatase
(G6Pase) and phosphoenolpyruvate carboxykinase (Pepck)
(Figure 6B) and found that they were both reduced in the
inhibitor-treated mice, in line with the finding of reduced blood
glucose levels in these animals.
Inhibition of Slc10a2 Reduces Akt and Mek1/2 Activity in
ob/ob Mouse Liver
To further study the molecular mechanisms underlying the
observed changes in hepatic gene transcription in the inhibitor-
treated ob/ob mice, we examined the activity of major kinase
signal pathways known to be important in hepatic regulation of
both glucose metabolism and lipogenesis. Akt has been demon-
strated to be a crucial component in regulating the hepatic
response to insulin and other circulating factors with capacity to
favour glycolysis and lipogenesis, and inhibit gluconeogenesis upon
food intake. The induction of Srebp1c transcription by insulin is
dependent on an Akt pathway [23]. When Akt activity was
evaluated by phosphospecific antibodies, a reduced serine 473
phosphorylation was noted in liver lysates from inhibitor-treated
animals (Figure 7A). Another kinase pathway activated by the
insulin receptor and the FGFr4/beta-Klotho complex (the FGF15
receptor), is the Mek1/2– Erk1/2 pathway [24,25]. Interestingly,
we found that also these important kinases displayed reduced
activation in ob/ob livers upon Slc10a2 inhibition (Figure7B).
Inhibition of Slc10a2 and Sucrose Diet Induces Hepatic
FGF21 mRNA
We have previously found that the mRNA levels for the
metabolic regulator FGF21 are increased 12-fold in ob/ob livers
compared to those of wt animals [26] and administration of
FGF21 reduces serum TGs, insulin and glucose [27]. We here
found that ob/ob mice treated with the Slc10a2 inhibitor doubled
their hepatic mRNA levels of FGF21 (Figure 5C). To gain further
insight in FGF21 regulation we determined FGF21 expression also
in the previous sucrose feeding experiment. The basal FGF21
Figure 6. Inhibition of Slc10a2 reduces mRNA levels of enzymes in fatty acid and glucose metabolism. Ob/ob mice were treated with
the specific Slc10a2 protein inhibitor, AZD7806 or control vehicle (Controls) (see experimental procedures). (A) Hepatic mRNA levels of Srebp1c, and
its target genes acetyl-CoA carboxylase (Acc), fatty acid synthase (Fas) and stearoyl-CoA desaturase 1 (Scd1). (B) Hepatic mRNA levels of glucokinase
(Gk), pyruvate kinase (Lpk), glucose 6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (Pepck) mRNA levels of the control vehicle
treated animals are normalized to 1. Data are represented as mean 6 standard error (SEM). Significances of differences between groups was tested by
Student’s t test, a p-value ,0.05 is denoted *.
doi:10.1371/journal.pone.0037787.g006
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compared to wt mice, and consumption of the SR diet increased
FGF21 mRNA levels strongly in both wt and Slc10a22/2 mice
(Figure 3F).
Discussion
While describing novel findings on lipid and carbohydrate
metabolism in Slc10a22/2 mice, this study also extends previous
observations made in this animal model. Slc10a2 disruption
increases the faecal loss of BAs that in turn strongly induces BA
synthesis [2]. In line with this, Cyp7a1 mRNA levels were
increased 7.5-fold as was the protein mass of Cyp7a1. The
enzymatic activity of the Cyp7a1 protein was also induced but the
level of induction was merely 2.5-fold. Together with the C4 data
this suggests that substrate availability for BA synthesis may be
limited in Slc10a22/2 mice having a major chronic loss of BAs.
Plasma cholesterol was unaltered in Slc10a22/2 animals.
Interestingly, plasma TGs showed a significant gene-dose depen-
dent 35% reduction in Slc10a22/2 mice as compared to wt
controls. Further, the gene expression of four enzymes important
in fatty acid synthesis (Acl, Acc, Fas and Scd1) was uniformly
reduced indicating a suppressed hepatic synthesis of TG. In line
with this, total TGs in the livers of Slc10a22/2 mice tended to be
lowered, although not reaching statistical significance. The
emerging pattern of a generally reduced hepatic synthesis of
Figure 7. Pharmacological inhibition of Slc10a2 induces altered activity of important signal transduction pathways in ob/ob liver.
The activation state of selected kinases important in glucose and lipid metabolism were investigated in individual liver protein extracts by
phosphorylation site-specific antibodies in Slc10a2 inhibitor-treated and control ob/ob mice. (A) Western blot against liver pAkt (ser 473), the same
membrane was stripped and reprobed with an antibody against total amount of Akt, (B) western blot against liver pMek1/2 (ser 217/221) and pErk1/
2 (Thr 202/Tyr 204), the same membranes were consecutively stripped and reprobed with antibodies against total Mek1/2 and Erk1/2. All membranes
were finally reprobed with an antibody against beta-actin. Blots are representative of four individual runs.
doi:10.1371/journal.pone.0037787.g007
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showed a gene dose-dependent reduction in Slc10a2-deficient
mice both at mRNA and protein levels.
In contrast to the situation for Srebp1c, the levels of Srebp2
mRNA were increased in Slc10a22/2 mice, presumably as a
response to an increased demand for cholesterol. In line with
this, HMG-CoA synthase and HMG-CoA reductase mRNA
levels - and enzymatic activity of the latter - were all increased in
Slc10a22/2 mice. Further evidence for an induced cholesterol
deficiency in the hepatocytes was the finding of reduced gene
expression for Abcg5 and Abcg8. These cholesterol transporters
are induced by oxysterols via the nuclear receptor Lxra [28].
Our finding of a discordant regulation of Srebp1c and Srebp2
mRNA is not unique, and has previously been reported following
treatment of rats with a combination of a BA binding resin and
mevinolin [29,30]. Notably, there was no increase in the gene
expression of the LDL receptor, which is known to show a more
sluggish regulatory response compared to that of HMG-CoA
reductase in mice [31].
Thus, in Slc10a22/2 animals, having a primary loss of BAs,
regulatory responses were found not only in the pathway for
cholesterol synthesis but also in pathways for TG synthesis.
Important structures in carbohydrate metabolism were also altered
in Slc10a22/2 mice. The mRNA levels of Gk, Lpk and Me were
all lower in Slc10a22/2 mice on chow as compared to wt
animals, whereas the message levels of G6pdh were increased.
This concerted response should preserve the availability of plasma
glucose and may result in a reduced formation of acetyl-CoA, a
mutual substrate for fatty acid and isoprenoid synthesis. The
metabolic demand for acetyl-CoA, utilized in isoprenoid synthesis,
should be increased in Slc10a22/2 animals mirrored by the 3-
fold increase in cholesterol synthesis in these animals (Figure 2D).
Animals were then challenged with a SR diet to unmask
metabolic differences between wt and Slc10a22/2 mice related to
lipogenesis. It was then found that Slc10a22/2 mice had lower
levels of liver cholesterol and TG than wt mice on the SR diet.
Strikingly, the levels of Srebp1c were retained at low levels even
under conditions of excess substrate availability for lipogenesis,
suggesting that powerful regulatory factors acting upstream of
Srebp1c are specifically targeted when Slc10a2 function is
abrogated. Thus, as judged from the increase in liver TG and
cholesterol, as well as from the level of TG synthesis in the livers,
Slc10a22/2 mice were more resistant to the SR diet than controls
(Figures 3A and 3B).
However, following the SR-diet, the induced BA and cholesterol
syntheses present in Slc10a22/2 mice were both reduced to levels
seen in wt animals following the SR-diet. Thus, the higher
resistance to the SR-diet in Slc10a22/2 animals could not simply
be ascribed to the increased cholesterol and BA synthesis seen in
these animals on regular chow. The reason for why BA synthesis
was suppressed by the SR-diet is unclear, although we found that
the intestinal gene expression of FGF15 was increased by 10-fold
in Slc10a22/2 mice reaching the same level as in wt mice on this
diet (Figure 4E). Given that intestinal FGF15 strongly inhibits
hepatic BA synthesis after binding to FGFR4 in the liver [32] this
may be one important reason for why the hepatic synthesis of BAs
was lowered. However, the mechanism by which a SR-diet
induces the gene expression for FGF15 in the intestine is unclear.
Since these animals lack functional Slc10a2– which in the mouse
appears to be the only major mechanism of active BA uptake from
the intestine [2] it seems more likely that other factors than BAs
may explain this remarkably strong stimulation of intestinal
FGF15. Clearly, further studies are needed to understand this
unexpected response.
To further explore our findings on altered lipogenesis in the
Slc10a22/2 mice, we investigated the effects of Slc10a2
inhibition in ob/ob mice. This model of leptin deficiency is
associated with peripheral insulin resistance, massive obesity and
fatty liver, but may not fully represent a type 2 diabetic state. We
previously showed that ob/ob mice display a suppressed BA
synthesis [16]. As expected, these mice responded to Slc10a2
inhibitor administration with elevated Cyp7a1 (Figure 5C) and
HMG-CoA reductase mRNA levels (not shown) while the serum
levels of insulin, TG and blood glucose were all markedly reduced
(Figures 5A and 4B).
Recently, studies utilizing BA binding resins have shown
reductions in blood glucose and serum TG levels in ob/ob
animals, and also in human diabetic subjects [33,34]. Together
with the present results, this implies that an elevated production
and faecal excretion of BAs would contribute to reduce serum
insulin and blood glucose levels when pathologically high.
However, there are fundamental differences between the use of
BA binding resins and disruption of Slc10a2 function with respect
to the resulting BA pool size and composition. Specific elimination
of Slc10a2 or blocking of Slc10a2-mediated BA uptake will lead to
a an increased faecal loss of BAs and a reduced BA pool [2].
However, the thereby increased input of primary BAs into the
large intestine will increase the formation of secondary, lipophilic
BAs such as deoxycholic acid (DCA) capable of efficient feed-back
inhibition of BA synthesis. This should somewhat lower the BA
synthesis response and impede the restoration of the BA pool. BA
binding resins on the other hand, at least in the human situation,
render the resin-bound BAs unavailable to bacterial degradation
into secondary BAs by resident microorganisms within the
intestine. Therefore, both the levels and the relative proportion
of secondary BAs such as DCA are reduced following resin
treatment, which in turn will promote the stimulation of BA
synthesis [35,36] that will restore or even expand the BA pool [36].
However, it must be remembered that there are several major
species differences as regards BA synthesis and its regulation [37].
In a recent study where a BA-binding resin was given to lean
and db/db mice, it was found that the reduction of blood glucose
and serum TGs was accompanied by an increased hepatic
lipogenesis actually worsening the liver fat accumulation in these
animals [36]. This response was concomitant with increased levels
of hepatic Srebp1c and its target genes [36]. This adverse response
of the db/db mice was shown to relate to intact Lxr and Fxr
function, since Lxr- and Fxr-deficient mice given the resin did not
respond with elevated Srebp1c levels. In the present study, we
demonstrated that ablation of Slc10a2 instead resulted in reduced
levels of both Srebp1c mRNA and mature protein which likely
contributed to the resistance of lipogenesis in response to the SR
diet in this model (Figure 3). Interestingly, this effect on Srebp1c
was also evident when Slc10a2 was pharmacologically blocked in
ob/ob mice (Figure 6A). Accordingly, the hepatic TG content was
not increased under these conditions (Figure 5D). This denotes a
major mechanistic difference between BA-binding resins and
Slc10a2 inhibitors in mice at the diabetic state, which has
previously not been demonstrated.
To seek further mechanistic explanation to the blunted
induction of lipogenesis, we investigated the PI3K and Akt
signalling pathway, known to be involved in Srebp1c induction by
insulin. [23]. We found that the important signalling intermediate
Akt displays a reduced hepatic activation in ob/ob animals treated
with the inhibitor (Figure 6A). It is well known that, despite the
reduced capacity of the insulin receptor to transmit signals in the
liver of ob/ob mice, some downstream signal targets, including
Srebp1c, are still overactive and may drive the formation of lipids
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observed reduction of Srebp1c. Whereas Akt1 is ubiquitously
expressed, Akt2 is predominantly found in the liver and other
insulin responsive organs. Interestingly, Akt2 seems to have
overlapping functions with Akt1 with regards to metabolism,
and in a recent report describing liver-specific deletion of Akt2 in
ob/ob mice it was found that these animals have reduced hepatic
production of lipids with lowered mRNA levels of Srebp1c and its
target genes Fas and Acc [39]. Since the antibodies employed to
detect the ser473-phosphorylated and total Akt are known to
recognize both Akt1 and Akt2, this assay cannot distinguish what
variants that are affected by the inhibitor treatment (Figure 6A).
Another pathway utilized by several cell surface receptors,
including receptor tyrosine kinases like the insulin receptor, is the
classical Mek1/2– Erk1/2 pathway [40]. We found this main
pathway to be suppressed in the liver under conditions of Slc10a2
inhibition. This reduction was also observed in the Slc10a2+/2
and Slc10a22/2 livers in a dose dependent manner (not shown).
Interestingly, this pathway is also shared with the FGFr4 and its
co-receptor beta-Klotho, serving as an FGF15 receptor complex
[25]. Thus, a reduction in activity of this pathway may be a
prerequisite for the induction of BA production via Cyp7a1. It is in
this respect also of interest to note that when mice deficient in
FGFr4 are challenged with a high fat diet, they respond with lower
hepatic TG production as compared to wt controls [24]. In this
sense, abrogation of Slc10a2, with dramatically reduced levels of
the FGFr4 ligand, FGF15, would likely mimic this situation with
respect to induction of hepatic lipogenesis upon dietary challenge.
FGF15 and FGF19 have been shown to have effects on energy
metabolism. Overexpression or injection of FGF19 into mice has
been shown to affect metabolic rate and improves insulin
resistance and dyslipidemia. It must be noted that these studies
have rendered FGF15/FGF19 plasma levels several powers of
magnitude higher than those observed at normal conditions in a
healthy human/animal. In a previous study by Moschetta and
colleagues [41] it was shown that Slc10a22/2 mice have very low
levels of FGF15 mRNA in the distal part of the small intestine. We
could confirm this finding in the current report. It is therefore
unlikely that FGF15 contributes to the positive antidiabetic effects
observed in this study when an Slc10a2 inhibitor was adminis-
trated to ob/ob animals. Instead, we demonstrate that in
accordance with studies using BA binding resins, FGF15 is not
essential for improved plasma lipid or glucose levels.
The recently discovered metabolic regulator FGF21 was
doubled in ob/ob mice receiving the Asbt inhibitor (Figure 5C)
and was increased by 4-fold in Slc10a22/2 mice (Figure 3F).
Since treatment of ob/ob or db/db mice with high doses of
FGF21 reduces elevated blood sugar and TGs [27] it may be
possible that FGF21 is involved in the reduction of blood glucose
and TGs in ob/ob mice and in the reduction of TGs in
Slc10a22/2 mice. However, the facts that FGF21 is already
increased over 10-fold in ob/ob mice [26] and that FGF21 was
strongly increased up to 25-fold upon challenge with the SR diet
to wt or to Slc10a22/2 mice do not support such a possibility.
An alternative explanation may be that Slc10a22/2 and ob/ob
mice have at the basal level an increased level of metabolic stress
as can also be induced in animals challenged with high doses of
dietary sucrose or an Asbt inhibitor. It is known that mice
respond with increased hepatic expression of FGF21 when
subjected to fasting [42] or to high energy diets [43]. Thus, the
limited 1-fold stimulation of hepatic FGF21 mRNA during
treatment with an Asbt inhibitor does not appear a likely
explanation for why plasma glucose is reduced.
Recently, the nuclear receptors RAR-related orphan receptor
(Ror)a and Rorc were shown to bind 7alpha-hydroxycholesterol
with high affinity [44]. Binding of these compounds was
demonstrated to repress the transcription of both Pepck and
G6Pase in a Ror-dependent manner. It was suggested that an
increased activity of Cyp7a1 would repress the hepatic glucose
output via increased availability of ligands for these Rors [44]. It
may be speculated that the decrease in Pepck and G6Pase
observed in our study could in part also relate to an increased
gene-specific repression exerted by these nuclear receptors.
In summary, this work demonstrates that abrogation of the ileal
BA transporter Slc10a2 leads to reduced serum TG levels with
concomitantly lowered hepatic Srebp1c levels. This feature is
further pronounced when Slc10a2 animals are challenged with a
lipogenic diet, manifested by a suppressed hepatic lipogenesis. Our
work also reveals novel mechanistic differences between the use of
BA-binding resins and specific inhibition of the ileal BA
transporter in the diabetic ob/ob model. Inhibition of Slc10a2
appears to be a more favourable option in treating elevated serum
TG and blood glucose levels, since it does not exert the adverse
effects on lipogenesis seen with BA binding resins.
Further studies are needed to define the global hormonal
response including intestinal incretins, and the precise pathways
affected in the liver under conditions of Slc10a2 functional
abrogation in the diabetic state, and could lead to novel
therapeutic interventions in hyperlipidemic states of disease,
including type 2 diabetes.
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